Merck close to buying Acceleron for $11B - report

Tuesday, 28. September 2021 01:15

Merck and Co. is nearing a deal to buy Acceleron Pharma Inc., the Wall Street Journal reported. The agreement could be announced this week, anonymous sources said.

The biopharmaceutical company is valued at around $11 billion. It specializes in cellular growth and repair, producing treatments for serious and rare pulmonary and blood diseases.

Related Links: Merck KGaA
Breaking the News / DJ